Proteomic Analysis of Human Hepatocellular Carcinoma
Primary Purpose
Carcinoma, Hepatocellular
Status
Completed
Phase
Not Applicable
Locations
Taiwan
Study Type
Interventional
Intervention
Operation
Sponsored by
About this trial
This is an interventional basic science trial for Carcinoma, Hepatocellular focused on measuring Carcinoma, hepatocellular, Portal vein, Proteomics
Eligibility Criteria
Inclusion Criteria:
Arm A: Hepatocellular carcinoma with vessel invasion:
- hepatocellular carcionoma, pathologic diagnosed.
- image documented vessel invasion, including portal vein thrombosis
- eligible for surgical intervension.
Arm B: hepatocellular carcinoma without vessel invasion:
- hepatocellular carcinoma, pathologic diagnosed or clinical diagnosed according to EASL criteria.
- no vessel invasion on image.
Arm C: Healthy hepatitis carrier:
- patients age >18 years old with hepatitis B or C
- normal liver function.
Sites / Locations
- Far Eastern Memorial Hospital
Outcomes
Primary Outcome Measures
Recurrence
Evidence of clinically definite vascular invasion of hepatocellular carcinoma. Confirmed by operation. Compare the proteomic expression of tumor, non-tumor ans tumor tissue in vascular part.
Secondary Outcome Measures
Full Information
NCT ID
NCT01177631
First Posted
June 2, 2009
Last Updated
February 4, 2016
Sponsor
Far Eastern Memorial Hospital
1. Study Identification
Unique Protocol Identification Number
NCT01177631
Brief Title
Proteomic Analysis of Human Hepatocellular Carcinoma
Official Title
Proteomic Analysis of Human Hepatocellular Carcinoma Associated With Portal Vein Thrombosis
Study Type
Interventional
2. Study Status
Record Verification Date
February 2016
Overall Recruitment Status
Completed
Study Start Date
February 2009 (undefined)
Primary Completion Date
January 2010 (Actual)
Study Completion Date
January 2010 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Far Eastern Memorial Hospital
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a pilot study to evaluate the difference between the protein expression between hepatocellular carcinoma and tumor with vessel invasion in Asian patients with hepatocellular carcinoma.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Carcinoma, Hepatocellular
Keywords
Carcinoma, hepatocellular, Portal vein, Proteomics
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
5 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Procedure
Intervention Name(s)
Operation
Intervention Description
Operation for clinically evaluated resectable hepatocelluar carcinoma. Compare the different expression of protein between tumor, non-tumor and tumor with vascular invasion part.
Primary Outcome Measure Information:
Title
Recurrence
Description
Evidence of clinically definite vascular invasion of hepatocellular carcinoma. Confirmed by operation. Compare the proteomic expression of tumor, non-tumor ans tumor tissue in vascular part.
Time Frame
one year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Arm A: Hepatocellular carcinoma with vessel invasion:
hepatocellular carcionoma, pathologic diagnosed.
image documented vessel invasion, including portal vein thrombosis
eligible for surgical intervension.
Arm B: hepatocellular carcinoma without vessel invasion:
hepatocellular carcinoma, pathologic diagnosed or clinical diagnosed according to EASL criteria.
no vessel invasion on image.
Arm C: Healthy hepatitis carrier:
patients age >18 years old with hepatitis B or C
normal liver function.
Facility Information:
Facility Name
Far Eastern Memorial Hospital
City
Taipei
ZIP/Postal Code
220
Country
Taiwan
12. IPD Sharing Statement
Learn more about this trial
Proteomic Analysis of Human Hepatocellular Carcinoma
We'll reach out to this number within 24 hrs